Company intelligence / Profile preview
Insmed Incorporated
Bridgewater, New Jersey, United Statesinsmed.com ↗
- Ownership
- Public · INSM
- Development stage
- Other
01
Overview
Insmed has received FDA accelerated approval for its first therapy, Arikayce (liposomal amikacin for inhalation), which is indicated for mycobacterium avium complex lung infection. The product is also approved in Europe and Japan. The company has multiple other candidates in clinical development.
- Therapeutic areas
- Rare DiseasesPulmonologyCardiovascularInfectious Diseases
- Modalities
- Small moleculesLiposomal technologyOligonucleotidesGene therapies
- Industry
- Biotech
02
Drug pipeline
31 assets30 more assets in the full pipeline.
03
Partnerships
AstraZeneca (worldwide license agreement in 2016)
04
Financials
- Market cap
- $23.9B
- Total revenue
- $606.4M
- Enterprise value
- $23.5B
Beyond the preview
Go deeper on Insmed Incorporated.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Insmed Incorporated.